Streetbeat News

Analyst Ratings

ADUS

Analysts have provided mixed reviews on Addus HomeCare (NASDAQ:ADUS) with a general positive outlook. The average 12-month price target has increased by 3.9% to $140.12. Analysts have raised their ratings and price targets, indicating a positive sentiment towards the company's future performance. Addus HomeCare has shown a positive revenue trend and strong net margin, but faces challenges with return on equity.

Portfolio Pulse from Benzinga Insights

September 23, 2024 | 2:00 pm

VZ

Analysts have mixed views on Verizon Communications (NYSE:VZ) with recent evaluations showing a slight positive shift in price targets. The average 12-month price target has increased by 1.6% to $45.21. Verizon's financial performance shows strong profitability and effective asset utilization, but high debt levels pose potential challenges.

Portfolio Pulse from Benzinga Insights

September 23, 2024 | 2:00 pm

PRGS

Progress Software Corporation (NASDAQ:PRGS) is set to release its Q3 earnings, with analysts expecting an EPS of $1.14 and revenue of $175.94 million. The company recently announced an $875 million acquisition of ShareFile. Analysts have varied ratings, with price targets ranging from $55 to $68.

Portfolio Pulse from Avi Kapoor

September 23, 2024 | 1:57 pm

ADUS

Oppenheimer analyst Michael Wiederhorn has maintained an 'Outperform' rating on Addus HomeCare (NASDAQ:ADUS) and raised the price target from $140 to $145.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 1:57 pm

CCI

JP Morgan analyst Richard Choe maintains a Neutral rating on Crown Castle (NYSE:CCI) but raises the price target from $115 to $124.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 1:57 pm

ABNB

Cantor Fitzgerald analyst Deepak Mathivanan has reiterated an Underweight rating on Airbnb (NASDAQ:ABNB) and maintained a price target of $94.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 1:57 pm

BMY

BMO Capital has maintained its Market Perform rating and $48 price target for Bristol-Myers Squibb, as stated by analyst Evan Seigerman.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 1:55 pm

BIIB

Wedbush analyst Laura Chico maintains a Neutral rating on Biogen (NASDAQ:BIIB) and lowers the price target from $210 to $205.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 1:53 pm

CDE

BMO Capital has maintained an 'Outperform' rating on Coeur Mining and raised its price target from $7.5 to $8, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 1:53 pm

BHVN

FUFU

TSLA

WULF

Biohaven Ltd. shares surged 18.4% after positive study results for Troriluzole. Other stocks like BitFuFu, TeraWulf, and Tesla also saw gains, with Tesla's rise linked to a reiterated Neutral rating by Cantor Fitzgerald.

Portfolio Pulse from Avi Kapoor

September 23, 2024 | 1:53 pm